Keyword: United Kingdom

Pfizer has come up short in a long-running patent battle in the U.K. over its blockbuster Lyrica, potentially costing the drugmaker.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

A U.K. court nixed a patent extension for Gilead's Truvada, potentially allowing for widespread use of generics as a pre-exposure prophylaxis.

NICE said yes to Novartis’ Tafinlar and Mekinist in adjuvant melanoma, giving the company a head start over rival BMS.

Pharma may have Trump administration allies, but across the pond, Health Minister Matt Hancock has attacked, aiming his toughest remarks at Vertex.

In advance of Brexit next year, Novo Nordisk plans a 4-month stockpile of critical insulins. The company is the largest insulin provider in the U.K.

England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.

CDC officials have been pushing HPV vaccination, and in 2017—just as in the previous four years—those efforts yielded only a slight increase.

England's NHS is mandating that all drugmakers stockpile an extra six weeks' worth of drugs in the country in case Brexit goes badly.

AstraZeneca has booted its contractor and pushed back its move-in date—again—for a project that's now $200 million over its original budget.